Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Latest Information Update: 22 Jul 2021
At a glance
- Drugs Alisertib (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Neuroendocrine tumours; Pancreatic cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 10 Jul 2021 Results evaluating the safety and maximum tolerated dose (MTD) of alisertib in combination with nab-paclitaxel and its preliminary efficacy in patients with refractory high-grade neuroendocrine tumours (NETs) published in the European Journal of Cancer
- 09 Jan 2018 Status changed from active, no longer recruiting to completed.
- 17 Jul 2017 Planned End Date changed from 30 Jun 2017 to 31 Dec 2017.